Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
about
The average body surface area of adult cancer patients in the UK: a multicentre retrospective studyDrug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureBody surface area formulae: an alarming ambiguityAssociation of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective reviewA phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.Correlates of 25-hydroxyvitamin D and breast cancer stage in the Women's Healthy Eating and Living Study.Technical note: Criterion validity of whole body surface area equations: a comparison using 3D laser scanning.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I studyPharmacogenetics in the treatment of breast cancer.Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid SystemsPopulation pharmacokinetics of raltitrexed in patients with advanced solid tumoursCalculation of body surface area via computed tomography-guided modeling in domestic rabbits (Oryctolagus cuniculus).Pharmacokinetic variability of anticancer agents.A Framework for Analyzing the Whole Body Surface Area from a Single View.Body surface assessment with 3D laser-based anthropometry: reliability, validation, and improvement of empirical surface formulae.Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupIntra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.Sarcopenia and chemotherapy-mediated toxicityTreatment of metastatic colorectal cancer in the elderly.Cost savings from dose rounding of biologic anticancer agents in adults.Therapeutic drug monitoring in cancer chemotherapy.A guide to rational dosing of monoclonal antibodies.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.
P2860
Q21142666-E1AE3790-9123-442D-B0EE-61416C72694EQ26766244-C44B87E2-DA7D-4C96-9431-CC5B8E2CF792Q27340024-84285EFA-6EBD-4EA9-9CB5-773F0F4B6F22Q28545175-4F63A747-C8D4-4DFF-8DFA-C63F56C0DEE6Q33368776-997B8B84-87B6-4F97-8538-CE847511C018Q33384540-5C34BEA3-10FC-407E-B658-C38F87DA287FQ33697742-35DCA034-7E0E-4E84-A2D2-BF310C3C2B39Q34213227-6CE16D76-3D5E-4028-9BB9-4F34CE4789A7Q34612932-DCBCA02C-9924-4945-A9E0-3C0B37272DB4Q35032865-A24FDA83-4132-4605-812D-6E38E1D45EA8Q35557435-C0DBD4EF-201B-46B2-9A2D-E888C0BE246DQ35648472-88E33A0F-3836-49F8-9EF6-A0932147CA2DQ35687796-200D57EA-455F-400F-BA3B-120B0FBF0334Q35692680-00052B28-09B1-4F6B-9F4A-5274A817D4C8Q35750919-06CEE369-6769-440B-B10D-D51517073E0BQ35776220-211790F2-0AC2-41F7-88EA-6579AB77115EQ35817902-B5140D51-3E7F-4303-B450-3FC8C7280CF8Q35826027-3510BF7D-C732-48C9-9CAF-6EB872018486Q36019778-DE550ABD-0F60-4088-8C4C-6E6292672213Q36146910-1BD236F2-6CDC-409A-BEE0-9844D5237FF7Q36237760-10830AFC-CDD7-4686-AA25-A236D89234B2Q36263071-B4F0856D-694A-4E4C-B13D-E64F034D2CD0Q36611760-4B55FD3E-0A57-401E-8C9C-95E586E63620Q36776441-B36B6BB5-FA06-4017-B739-C704B9F49390Q36885663-5A434353-0CEA-4D7B-90D9-3D9B6A0F8707Q36904564-BD2334FD-52CB-4DD7-81BA-8FC3CC06D77EQ37120672-C9A2F292-1D76-4B95-B104-DC837B2BC598Q37400113-396C2D2C-45CE-4355-B3C4-2BB0E23A7055Q37477083-564594C3-EEA3-43B3-8BB5-C9D02E224823Q37572738-04058DF9-8353-4E30-8A3C-A435304B14E4Q37612945-EBBD10E8-5A51-4B35-A159-C6E85A90F15FQ37717856-6749B4A4-4991-46BF-B462-32B07240289FQ37810220-82B5FEA7-265A-43B1-980C-D09C482CD599Q37976878-0C94CEC3-6D9D-4E3B-83F8-7E2285076E9FQ38019839-198BC2AC-168E-44A2-BF22-B4ECE579ED63Q38130610-227CC285-8C4D-4ECA-85CB-FF6EB4CF7823Q38351470-E74E93FD-02B2-4DD7-B08F-FDAC117C0456Q38568180-221DFE73-03A7-47A3-AC20-B2F05CFCFA02Q39115623-6CB2FAED-34DB-4600-A187-4A01D763FE08Q39901051-8B794834-15B8-4A26-8B26-A4BF3E930924
P2860
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role of body surface area in d ...... r agents in adults, 1991-2001.
@ast
Role of body surface area in d ...... r agents in adults, 1991-2001.
@en
Role of body surface area in d ...... r agents in adults, 1991-2001.
@nl
type
label
Role of body surface area in d ...... r agents in adults, 1991-2001.
@ast
Role of body surface area in d ...... r agents in adults, 1991-2001.
@en
Role of body surface area in d ...... r agents in adults, 1991-2001.
@nl
prefLabel
Role of body surface area in d ...... r agents in adults, 1991-2001.
@ast
Role of body surface area in d ...... r agents in adults, 1991-2001.
@en
Role of body surface area in d ...... r agents in adults, 1991-2001.
@nl
P2093
P356
P1476
Role of body surface area in d ...... r agents in adults, 1991-2001.
@en
P2093
Eric K Rowinsky
Jaap Verweij
Jan H M Schellens
Louise B Grochow
Ross C Donehower
Sharyn D Baker
P304
P356
10.1093/JNCI/94.24.1883
P407
P577
2002-12-01T00:00:00Z